*Funding information* No funding

Introduction {#bjs550178-sec-0005}
============

Abdominal aortic aneurysms (AAAs) involving, or in close proximity to, the renal arteries pose a significant challenge during both open surgical repair (OSR) and endovascular aneurysm repair (EVAR)[1](#bjs550178-bib-0001){ref-type="ref"}. In 2010, the Society for Vascular Surgery *Ad Hoc* Committee on TEVAR (thoracic EVAR) released the classification of AAA and thoracoabdominal aortic aneurysm (TAAA)[2](#bjs550178-bib-0002){ref-type="ref"}. It defined juxtarenal aneurysms as those with no normal aorta between the upper

extent of the aneurysm and the renal arteries. The term suprarenal AAA describes aneurysms that extend above the renal arteries, but do not involve the thoracic aorta[3](#bjs550178-bib-0003){ref-type="ref"}. Crawford and colleagues[1](#bjs550178-bib-0001){ref-type="ref"} highlighted the additional challenges faced during OSR when the aneurysm extends to the renal arteries. These include additional exposure (ligation of the left renal vein, dissection of the renal arteries and superior mesenteric artery (SMA), or a retroperitoneal approach and mobilization of the left kidney), proximal aortic cross‐clamp placement (between the renal arteries and the SMA or above the coeliac trunk), and renal artery reconstruction or reimplantation. Rates of early mortality and haemodialysis in this series were both 8 per cent. Prolonged clamp time appeared to be an independent predictor of renal failure[1](#bjs550178-bib-0001){ref-type="ref"}. Modern outcomes are not dissimilar to those described by Crawford *et al.* ^1^. Deery and co‐workers[4](#bjs550178-bib-0004){ref-type="ref"} found 30‐day mortality rates to be three times higher after repair of juxtarenal AAA compared with standard infrarenal AAA intervention.

The morphology of a juxtarenal AAA makes it unsuitable for conventional EVAR (outside instructions for use) owing to the lack of a suitable proximal landing zone[5](#bjs550178-bib-0005){ref-type="ref"}. This has driven modifications to the EVAR technique in recent years, including development of the chimney EVAR (ChEVAR) (also known as the snorkel EVAR) and fenestrated EVAR (FEVAR), to provide an endovascular solution for these complex aneurysms. The literature supports the use of ChEVAR for urgent or bailout procedures but not for elective work[6](#bjs550178-bib-0006){ref-type="ref"}, [7](#bjs550178-bib-0007){ref-type="ref"}, supported by a recent meta‐analysis[8](#bjs550178-bib-0008){ref-type="ref"} that showed FEVAR to have lower 30‐day mortality, long‐term mortality and adverse renal events than ChEVAR. The aim of FEVAR is to exclude the aneurysm from the circulation while maintaining normal perfusion of the renal arteries, SMA and the coeliac trunk. FEVAR requires custom‐made stent grafts, with fenestrations created in the stent graft to match the ostia of the visceral vessels. The graft is inserted and oriented so that the fenestrations correspond to the target vessels. The visceral vessels are cannulated, and covered stent grafts are placed to provide a conduit between the main graft and the visceral arteries. Randomized trials[9](#bjs550178-bib-0009){ref-type="ref"}, [10](#bjs550178-bib-0010){ref-type="ref"} have compared EVAR and OSR in the treatment of infrarenal AAA and found EVAR to be associated with lower early morbidity and mortality. No such trial data exist with regard to the open or endovascular treatment of juxtarenal and suprarenal AAA. The aim of this systematic review was to examine the literature from the last 10 years for both FEVAR and OSR in the treatment of juxtarenal and suprarenal AAA.

Methods {#bjs550178-sec-0006}
=======

A literature search was conducted of the Ovid Medline and EMBASE databases to April 2017. Search terms included 'fenestrated endovascular repair', 'aneurysm', 'open repair' and 'juxta‐renal aneurysm'. A second search of PubMed was conducted, using the same search terms.

Inclusion and exclusion criteria {#bjs550178-sec-0007}
--------------------------------

Prospective and retrospective cohort studies, as well as case series involving more than 20 patients, published from 2007 onwards were included. Registry data were excluded to avoid duplication of data. When duplicate data were present, the most recent, complete findings were included for analysis. Studies pertaining to all forms of complex AAA were selected, including juxtarenal, pararenal and suprarenal. Owing to variance in definitions, the terms 'juxta/para/suprarenal' were considered sufficient for inclusion; strict anatomical definitions were not mandated. TAAA were excluded, including Crawford type IV. Where studies presented data from TAAA that could not be analysed separately from complex AAA, they were excluded. Only elective repairs were included, thereby excluding ruptures. When considering FEVAR, only series describing custom‐made fenestrated devices were included. This excluded 'off the shelf' devices and physician‐modified grafts. All other forms of endovascular repair, including chimney and snorkel repairs and branched devices, were excluded. All forms of OSR were included, including transperitoneal and retroperitoneal approaches, and all variations of visceral vessel reconstruction.

Outcomes {#bjs550178-sec-0008}
--------

The primary outcomes were 30‐day/in‐hospital mortality and postoperative renal insufficiency. Secondary outcomes included major complication rates, postoperative permanent dialysis, rate of reintervention, long‐term survival and rates of endoleak. Definitions of renal insufficiency, acute kidney injury (AKI) and postoperative complications were as per individual study definition. This resulted in a heterogeneous definition of renal insufficiency, ranging from a serum creatinine rise of 30 per cent to a reduction in estimated glomerular filtration rate (eGFR) of more than 50 per cent. Major postoperative complications were defined as per individual

study definitions, and included cardiac, pulmonary, renal, mesenteric, neurological and surgical‐site complications, and return to theatre. Secondary reinterventions were defined as any intervention, whether open or endovascular, performed during the period of follow‐up for aneurysm or graft‐related complications.

Statistical analysis {#bjs550178-sec-0009}
--------------------

The rates of each outcome were calculated per study using a meta‐analysis of proportions using MedCalc® statistical software (MedCalc software, Ostend, Belgium). The χ^2^ Cochrane Q score was used to assess study heterogeneity. Owing to significant heterogeneity, a random‐effects model was used and a pooled comparison was not performed.

Results {#bjs550178-sec-0010}
=======

The literature search identified 1547 potential articles. Following assessment this was refined to 27 studies, 14 involving FEVAR and 13 involving OSR, which were analysed using qualitative and quantitative methods. The PRISMA flow diagram is illustrated in *Fig*. [1](#bjs550178-fig-0001){ref-type="fig"}. Funnel plots were used to assess for risk of publication bias (*Fig*. *S1*, supporting information).

![PRISMA flow diagram. TAAA, thoracoabdominal aortic aneurysm; ChEVAR, chimney endovascular aneurysm repair](BJS5-3-572-g001){#bjs550178-fig-0001}

Study characteristics {#bjs550178-sec-0011}
---------------------

Of the 14 studies involving FEVAR, the study designs included five case series[11](#bjs550178-bib-0011){ref-type="ref"}, [12](#bjs550178-bib-0012){ref-type="ref"}, [13](#bjs550178-bib-0013){ref-type="ref"}, [14](#bjs550178-bib-0014){ref-type="ref"}, [15](#bjs550178-bib-0015){ref-type="ref"}, four series within retrospective cohort studies comparing FEVAR with other endovascular interventions[7](#bjs550178-bib-0007){ref-type="ref"}, [16](#bjs550178-bib-0016){ref-type="ref"}, [17](#bjs550178-bib-0017){ref-type="ref"}, [18](#bjs550178-bib-0018){ref-type="ref"}, three retrospective cohort studies that compared varying complexity of FEVAR[19](#bjs550178-bib-0019){ref-type="ref"}, [20](#bjs550178-bib-0020){ref-type="ref"}, [21](#bjs550178-bib-0021){ref-type="ref"}, one case--control study[22](#bjs550178-bib-0022){ref-type="ref"} and a single non‐randomized trial[23](#bjs550178-bib-0023){ref-type="ref"} (*Table* [1](#bjs550178-tbl-0001){ref-type="table"}). Eleven single‐centre and three multicentre studies were included, with study sizes ranging from 20 to 384 patients, and follow‐up from 1 to 67 months. Three series identified were from the UK, the largest of these being that of Roy and colleagues[11](#bjs550178-bib-0011){ref-type="ref"}, involving 173 patients over a follow‐up period of 34 months.

###### 

Design and baseline characteristics of fenestrated endovascular aneurysm repair studies

  Reference                             Study design            Country     Sites   *n*   Follow‐up (months)   Definition of early mortality  Definition of renal insufficiency         Aneurysm morphology
  ----------------------------- ---------------------------- ------------- ------- ----- -------------------- ------------------------------- ----------------------------------------- ------------------------------------------------------------------
  Oikonomou *et al.* ^19^           Retrospective cohort        Germany       1     141           33                      30 days             Reduction eGFR \> 30%                     Short‐necked, juxtarenal and suprarenal
  Roy *et al.* ^11^                     Case series               UK          1     173           34                    In‐hospital           \> 50% rise in creatinine                 n.s.
  Wooster *et al.* ^16^             Retrospective cohort          USA         1     39           6·7                    In‐hospital           n.s.                                      Extension to \< 4 mm of renal artery and not above highest renal
  Blankensteijn *et al.* ^12^           Case series           Netherlands    13     60           16·4                     30 days             n.s.                                      Neck length \< 15 mm and not extending above renal arteries
  Katsargyris *et al.* ^20^         Retrospective cohort        Germany       1     384           20                      30 days             \> 30% rise in creatinine                 Short‐necked, juxtarenal and suprarenal
  Caradu *et al.* ^7^               Retrospective cohort        France        1     90            19              30 days or in‐hospital      'Acute kidney injury' (definition n.s.)   n.s.
  Saratzis *et al.* ^22^               Case--control              UK          1     58            20                       n.s.               \> 50% rise in creatinine                 Short‐necked and juxtarenal (suprarenal excluded)
  Vemuri *et al.* ^13^                  Case series               USA         7     57           1·75                     30 days             n.s.                                      n.s.
  Kristmundsson *et al.* ^14^           Case series             Sweden        1     54            67                      30 days             \> 30% decrease in eGFR                   Short‐necked and juxtarenal (suprarenal excluded)
  Grimme *et al.* ^15^                  Case series           Netherlands     1     138           13                      30 days             \> 30% decrease in eGFR                   Short‐necked, juxtarenal and suprarenal
  Banno *et al.* ^17^               Retrospective cohort        France        1     80            14                      30 days             \> 50% rise in creatinine                 Short‐necked and juxtarenal (suprarenal excluded)
  Oderich *et al.* ^23^          Prospective non‐randomized       USA        14     67            37                      30 days             \> 30% decrease in eGFR in two tests      Neck length ≥ 4 mm and ≤ 15 mm
  Perot *et al.* ^18^               Retrospective cohort        France        1     115           20                      30 days             Creatinine clearance \< 60 ml/min         Suprarenal and juxtarenal
  Manning *et al.* ^21^             Retrospective cohort          UK          1     20            1                        n.s.               n.s.                                      n.s.

eGFR, Estimated glomerular filtration rate; n.s., not stated.

Of the 13 studies involving OSR, the study designs included six case series[24](#bjs550178-bib-0024){ref-type="ref"}, [25](#bjs550178-bib-0025){ref-type="ref"}, [26](#bjs550178-bib-0026){ref-type="ref"}, [27](#bjs550178-bib-0027){ref-type="ref"}, [28](#bjs550178-bib-0028){ref-type="ref"}, [29](#bjs550178-bib-0029){ref-type="ref"}, four retrospective cohort studies comparing OSR with FEVAR[30](#bjs550178-bib-0030){ref-type="ref"}, [31](#bjs550178-bib-0031){ref-type="ref"}, [32](#bjs550178-bib-0032){ref-type="ref"}, [33](#bjs550178-bib-0033){ref-type="ref"}, and three retrospective cohort studies comparing OSR of juxtarenal and infrarenal aneurysms[34](#bjs550178-bib-0034){ref-type="ref"}, [35](#bjs550178-bib-0035){ref-type="ref"}, [36](#bjs550178-bib-0036){ref-type="ref"} (*Table* [2](#bjs550178-tbl-0002){ref-type="table"}). Twelve single‐centre studies and one multicentre study were included, with study sizes ranging from 31 to 214 patients and follow‐up from 1 to 66 months.

###### 

Design and baseline characteristics of open surgical repair studies

  Reference                                                  Study design                  Country         Sites   *n*   Follow‐up (months)   Definition of early mortality  Definition of renal insufficiency                                                            Definition of juxtarenal/suprarenal aneurysm
  ---------------------------------------------------------- ---------------------- --------------------- ------- ----- -------------------- ------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------
  Van Lammeren *et al.* ^24^                                 Case series                 Netherlands         1     214          21·6                     30 days             n.s. (new‐onset eGFR \< 15 ml per min per l.73 m^2^ or dialysis recorded as renal failure)   Cross‐clamp above ≥ 1 renal artery
  Shahverdyan *et al.* ^30^                                  Retrospective cohort          Germany           1     34            66                      30 days             \> 50% rise in creatinine and/or \> 25% decrease in eGFR                                     Suprarenal or higher cross‐clamp
  Barillà *et al.* ^31^                                      Retrospective cohort           Italy            1     50           n.s.                     30 days             \> 30% rise in creatinine                                                                    [\*](#bjs550178-note-0003){ref-type="fn"}
  Canavati *et al.* ^32^                                     Retrospective cohort            UK              1     54            1               30 days or in‐hospital      \> 50% rise in creatinine                                                                    Aneurysm neck \< 10 mm
  Dubois *et al.* ^25^                                       Case series                   Canada            1     169           1                     In‐hospital           \> 25% decrease in eGFR                                                                      Suprarenal or higher cross‐clamp
  Tsai *et al.* ^26^                                         Case series                     USA             1     199           56                      30 days             Creatinine rise \> 0·5 mg/dl over baseline and \> 1·5 mg/dl                                  Suprarenal or higher cross‐clamp
  Donas *et al.* ^33^                                        Retrospective cohort          Germany           1     31           14·1                     30 days             Doubling of baseline creatinine or decrease in eGFR \> 50%                                   Suprarenal or higher cross‐clamp
  Jeyabalan *et al.* ^27^                                    Case series             USA and South Korea     2     184          26·4                      n.s.               Creatinine rise \> 0·5 mg/dl                                                                 Cross‐clamp above ≥ 1 renal artery
  Landry *et al.* ^34^                                       Retrospective cohort            USA             1     82            1                       30 days             Creatinine rise \> 0·5 mg/dl                                                                 Suprarenal or higher cross‐clamp
  Chong *et al.* [35](#bjs550178-bib-0035){ref-type="ref"}   Retrospective cohort            USA             1     171          56·7                     30 days             eGFR \< 30 ml per min per 1·73 m^2^ and \> 20% decrease in eGFR                              Suprarenal or higher cross‐clamp
  Knott *et al.* ^28^                                        Case series                     USA             1     126           48                      30 days             Creatinine rise \> 0·5 mg/dl                                                                 Cross‐clamp above ≥ 1 renal artery
  Pearce *et al.* ^29^                                       Case series                     USA             1     150           32              30 days or in‐hospital      \> 20% rise in creatinine and level \> 1·5 mg/dl in men, \> 1·3 mg/dl in women               Cross‐clamp above ≥ 1 renal artery
  Ockert *et al.* ^36^                                       Retrospective cohort          Germany           1     35           27·6                   In‐hospital           Doubling of baseline creatinine or creatinine level \> 1·3 mg/dl                             Suprarenal or higher cross‐clamp

Hostile neck defined as: length \< 10 mm, angle ≥ 60°, ≥ 50% calcified neck, diameter \> 31 mm, \> 50% circumferential thrombus, reverse taper configuration. eGFR, Estimated glomerular filtration rate; n.s., not stated.

Qualitative assessment revealed a large proportion of single‐centre case series with a lack of internal controls. The included retrospective cohort studies have a high risk of selection and recorder bias. The significant variability in length of follow‐up affects the validity of a number of secondary outcomes, in particular the incidence of reintervention. Variability of outcome reporting, particularly with respect to the definitions of renal insufficiency, exists within the selected series. Overall the quality of available evidence was low.

Baseline characteristics {#bjs550178-sec-0012}
------------------------

A total of 2975 patients were included, 1476 who underwent FEVAR and 1499 who had OSR. Baseline characteristics of the two groups are shown in *Table* [3](#bjs550178-tbl-0003){ref-type="table"}. Patients undergoing FEVAR had more medical co‐morbidities. Pre‐existing renal dysfunction was twice as high in the FEVAR cohort; these patients also displayed higher rates of ischaemic heart disease and pulmonary dysfunction. The breakdown of study design and patient characteristics is shown in *Tables* [1](#bjs550178-tbl-0001){ref-type="table"} and [2](#bjs550178-tbl-0002){ref-type="table"}.

###### 

Summary of baseline characteristics

                                                                       FEVAR        OSR
  ----------------------------------------------------------------- ----------- -----------
  Age (years)[\*](#bjs550178-note-0005){ref-type="fn"}               73·2(1·4)   72·1(2·5)
  Aneurysm diameter (cm)[\*](#bjs550178-note-0005){ref-type="fn"}    6·1(0·3)    6·3(0·4)
  Renal dysfunction                                                    37·8        16·7
  Ischaemic heart disease                                              54·5        49·5
  Pulmonary dysfunction                                                39·4        31·9
  Diabetes                                                             17·7        13·7

Values are percentages unless indicated otherwise;

values are mean(s.d.). FEVAR, fenestrated endovascular aneurysm repair; OSR, open surgical repair.

Mortality {#bjs550178-sec-0013}
---------

The pooled rate of early postoperative mortality following FEVAR was 3·3 (95 per cent c.i. 2·0 to 5·0) per cent, compared with 4·2 (2·9 to 5·7) per cent after OSR (*Fig*. [2](#bjs550178-fig-0002){ref-type="fig"}). Estimated long‐term survival was similar for FEVAR and OSR (*Tables* [4](#bjs550178-tbl-0004){ref-type="table"} and [5](#bjs550178-tbl-0005){ref-type="table"}).

![Thirty‐day/in‐hospital mortality after **a** fenestrated endovascular aneurysm repair (FEVAR) and **b** open surgical repair (OSR). A random‐effects model was used for meta‐analysis. Pooled rate of early postoperative mortality: **a** 3·3 (95 per cent c.i. 2·0 to 5·0) per cent; **b** 4·2 (2·9 to 5·7) per cent](BJS5-3-572-g002){#bjs550178-fig-0002}

###### 

Estimated long‐term survival after fenestrated endovascular aneurysm repair

                                                                  Survival after FEVAR (%)                       
  -------------------------------------------------------------- -------------------------- ------ ------ ------ ------
  Oikonomou *et al.* [19](#bjs550178-bib-0019){ref-type="ref"}              85·1              --    75·8    --     --
  Blankensteijn *et al.* ^12^                                               91·4             89·5   86·3    --     --
  Katsargyris *et al.* ^20^ (standard FEVAR)                                 95               --    83·4    --     --
  Katsargyris *et al.* ^20^ (complex FEVAR)                                  94               --    89·4    --     --
  Caradu *et al.* ^7^                                                       91·4             82·1    --     --     --
  Kristmundsson *et al.* ^14^                                                93               --     76     --     60
  Grimme *et al.* ^15^                                                      89·2             83·2   71·9   62·5   53·3
  Banno *et al.* ^17^                                                       83·9             77·3    --     --     --
  Oderich *et al.* ^23^                                                      97              95·2   90·7   90·7   90·7
  Perot *et al.* ^18^                                                       93·9              --     --     --     --

FEVAR, fenestrated endovascular aneurysm repair.

###### 

Estimated long‐term survival following open surgical repair

                               Survival after OSR (%)                       
  --------------------------- ------------------------ ------ ------ ------ ------
  Shahverdyan *et al.* ^30^             90·3            90·3    --     --     --
  Barillà *et al.* ^31^                  90              84     74     70     65
  Tsai *et al.* ^26^                    91·5            87·1   82·5   79·2   74·2
  Chong *et al.* ^35^                    --              --     --     --    67·7
  Knott *et al.* ^28^                    94              --     78     --     64
  Pearce *et al.* ^29^                   88              82     78     72     69

OSR, open surgical repair.

Postoperative renal insufficiency {#bjs550178-sec-0014}
---------------------------------

After FEVAR, the pooled rate of postoperative renal insufficiency was 16·2 (95 per cent c.i. 10·4 to 23·0) per cent, compared with 23·8 (15·2 to 33·6) per cent after OSR (*Fig*. [3](#bjs550178-fig-0003){ref-type="fig"}). The pooled rate of permanent dialysis was 0·8 (0·4 to 1·4) and 1·7 (1·0 to 2·5) per cent respectively.

![Renal insufficiency after **a** fenestrated endovascular aneurysm repair (FEVAR) and **b** open surgical repair (OSR). A random‐effects model was used for meta‐analysis. Pooled rate of postoperative renal insufficiency: **a** 16·2 (95 per cent c.i. 10·4 to 23·0) per cent; **b** 23·8 (15·2 to 33·6) per cent](BJS5-3-572-g003){#bjs550178-fig-0003}

Major postoperative complications {#bjs550178-sec-0015}
---------------------------------

Following FEVAR, the pooled major complication rate was 23·1 (95 per cent c.i. 16·8 to 30·1) per cent, compared with 43·5 (34·4 to 52·8) per cent after OSR. The rate of cardiac complications was 3·9 (1·8 to 6·9) and 13·4 (9·6 to 17·6) per cent respectively. Cardiac complications included myocardial infarction, cardiac arrhythmia and cardiac failure; however, this varied by study. Rates of myocardial infarction following FEVAR were 1·9 (0·4 to 4·7) per cent *versus* 5·8 (3·6 to 8·4) per cent after OSR. The pooled rate of mesenteric ischaemia was 2·2 (1·1 to 3·6) and 2·3 (1·3 to 3·6) per cent respectively.

Reintervention {#bjs550178-sec-0016}
--------------

The overall rate of early reintervention (at less than 30 days) after FEVAR was 6·1 (95 per cent c.i. 3·2 to 9·8) per cent, compared with 7·4 (4·7 to 10·7) per cent after OSR. The rate of late reintervention following FEVAR was higher than that after OSR: 11·1 (6·7 to 16·4) and 2·0 (0·6 to 4·3) per cent respectively (*Fig*. [4](#bjs550178-fig-0004){ref-type="fig"}), at a mean follow‐up of 21·6 and 31·1 months respectively.

![Late (more than 30 days) reintervention after **a** fenestrated endovascular aneurysm repair (FEVAR) and **b** open surgical repair (OSR). A random‐effects model was used for meta‐analysis. Late reintervention rate: 11·1 (6·7 to 16·4) per cent; **b** 2·0 (0·6 to 4·3) per cent](BJS5-3-572-g004){#bjs550178-fig-0004}

Rates of endoleak and occlusion after FEVAR {#bjs550178-sec-0017}
-------------------------------------------

Overall, the incidence of type I/III endoleak was 4·9 (95 per cent c.i. 2·6 to 7·9) per cent (*Fig*. [5](#bjs550178-fig-0005){ref-type="fig"}). Rates of target vessel preservation and long‐term patency are shown in *Table* [6](#bjs550178-tbl-0006){ref-type="table"}. Target vessel preservation was high, with rates of occlusion during follow‐up between 2 and 4 per cent.

![Combined rates of type I and type III endoleak. A random‐effects model was used for meta‐analysis. Incidence of type I/III endoleak: 4·9 (95 per cent c.i. 2·6 to 7·9) per cent](BJS5-3-572-g005){#bjs550178-fig-0005}

###### 

Target vessel preservation (excluding vessels targeted by scallops)

                                                                      No. of patients   No. of vessels targeted (fenestrations/stents)   Mean no. of fenestrations per patient   No. of vessels stented successfully   Operative target vessel preservation rate (%)   Stenosis requiring reintervention   Target vessel occlusion during follow‐up   Target vessel occlusion rate during follow‐up (%)
  ------------------------------------------------------------------ ----------------- ------------------------------------------------ --------------------------------------- ------------------------------------- ----------------------------------------------- ----------------------------------- ------------------------------------------ ---------------------------------------------------
  Oikonomou *et al.* ^19^                                                   141                              403                                         2·86                                   n.s.                                       n.s.                                       12                                      8                                             n.s.
  Roy *et al.* ^11^                                                         173                              446                                         2·58                                    440                                       98·7                                      n.s.                                     11                                             2·5
  Wooster *et al.* ^16^                                                     39                                99                                         2·53                                    99                                         100                                        1                                      0                                               0
  Blankensteijn *et al.* ^12^                                               60                               140                                         2·33                                    136                                       97·1                                        0                          4 (2 treated successfully)                                 2·9
  Katsargyris *et al.* [20](#bjs550178-bib-0020){ref-type="ref"}            384                              n.s.                                        n.s.                                   n.s.                                       n.s.                                      n.s.                                     11                                            n.s.
  Caradu *et al.* ^7^                                                       90                               198                                          2·2                                    196                                       99·0                                      n.s.                                    n.s.                                           n.s.
  Saratzis *et al.* ^22^                                                    58                               150                                         2·59                                   n.s.                                       n.s.                                      n.s.                            4 (of 116 followed)                                     3·5
  Vemuri *et al.* ^13^                                                      57                               120                                          2·1                                    117                                       97·5                                        0                                      0                                               0
  Kristmundsson *et al.* [14](#bjs550178-bib-0014){ref-type="ref"}          54                                96                                         1·78                                   n.s.                                        98                                       n.s.                                    n.s.                                           n.s.
  Grimme *et al.* ^15^                                                      138                              254                                         1·84                                    249                                       98·0                                      n.s.                                     10                                             3·9
  Banno *et al.* ^17^                                                       80                               194                                         2·42                                    189                                       97·4                                      n.s.                                    n.s.                                           n.s.
  Oderich *et al.* ^23^                                                     67                   127 (stented target vessels)                            1·90                                    127                                        100                                       11                                      4                                              3·1
  Manning *et al.* ^21^                                                     20                      47 (scallops included)                               2·35                                    65                                        95·6                                      n.a.                                    n.a.                                           n.a.

n.s., Not stated; n.a., not applicable.

Subgroup analysis by complexity of FEVAR {#bjs550178-sec-0018}
----------------------------------------

Four[11](#bjs550178-bib-0011){ref-type="ref"}, [19](#bjs550178-bib-0019){ref-type="ref"}, [20](#bjs550178-bib-0020){ref-type="ref"}, [21](#bjs550178-bib-0021){ref-type="ref"} of the 13 studies provide sufficient data to compare the outcomes of FEVAR according to anatomical complexity. Patients were divided into two groups according to the level of vessels that were stented. Standard FEVAR was defined as stenting of the renal arteries with or without a scallop for the SMA, and complex FEVAR was defined as stenting of the renal arteries as well as the SMA and/or coeliac trunk. The groups consisted of 337 and 381 patients respectively. The data suggested a trend towards increased mortality with more complex repair, although this was not statistically significantly different (relative risk (RR) 1·38, 95 per cent c.i. 0·37 to 5·20; *P* = 0·634). There was no difference in technical success (RR 1·19, 0·95 to 1·01) or major complication (RR 1·19, 0·75 to 1·89) rates. Spinal cord ischaemia occurred only in patients who had undergone complex FEVAR (RR 4·71, 0·84 to 26·39), although this difference was not significantly different (*P* = 0·077). Rates of target vessel preservation and patency, and rates of endoleak were both reported inconsistently among studies. Reintervention rates were no different between standard and complex FEVAR groups (RR 0·90, 0·61 to 1·33; *P* = 0·343).

Discussion {#bjs550178-sec-0019}
==========

RCTs[10](#bjs550178-bib-0010){ref-type="ref"}, [37](#bjs550178-bib-0037){ref-type="ref"} have shown that the early safety profile of EVAR is better than that of OSR in the treatment of infrarenal AAA. A recent systematic review[38](#bjs550178-bib-0038){ref-type="ref"} of these trials found the postoperative mortality rate associated with EVAR and OSR for infrarenal aneurysm to be 1·3 and 4·7 per cent respectively. This difference in early safety profile may not translate to the endovascular management of complex AAA. This review found similar mortality figures for FEVAR and OSR. These findings are supported by a previous review by Rao and colleagues[39](#bjs550178-bib-0039){ref-type="ref"}, which found a postoperative mortality rate of 4·1 per cent after both FEVAR and OSR. This may suggest that the physiological effects of treating the visceral segment are greater than those with a simple EVAR. It may also reflect the significantly co‐morbid patient cohort undergoing FEVAR in the studies analysed. Alternatively, it may reflect a lower than expected mortality rate in the OSR cohort, owing to the inclusion of trial data and publication bias, and may not reflect real‐world outcomes.

There is debate surrounding the long‐term renal implications of EVAR. FEVAR includes additional factors that place patients at risk of short‐ and long‐term renal complications: extensive instrumentation of the aorta and renal arteries to deploy the fenestrations, use of increased quantities of iodinated contrast, and increased risk of endoprosthesis failure necessitating further intervention. The renal risks of OSR stem from the ischaemic effects of suprarenal clamping, as well as the systemic response generated from significant surgery. The results of the present study suggest that, despite the large disparity in preoperative renal function, the incidence of renal impairment following FEVAR was lower than that after OSR. The incidence of permanent dialysis after OSR was 1·7 per cent, compared with 0·8 per cent after FEVAR. Long‐term renal outcomes were reported inconsistently in the included studies, and thus meaningful meta‐analysis cannot be performed. It should be noted that the heterogeneity of reporting and defining renal function limits the conclusions that can be drawn. Some studies reported renal insufficiency according to the RIFLE (risk, injury, failure, loss and end‐stage renal disease) criteria and defined it as either an increase in eGFR greater than 30 per cent from baseline or as a decrease in eGFR of more than 50 per cent from baseline, whereas others used use change in creatinine levels. It might be assumed that postoperative dialysis rates would provide a more reliable outcome, but studies varied when providing data regarding permanent or temporary dialysis; Pearce *et al.* ^29^ described 'acute dialysis', and did not state whether this was permanent or temporary.

High levels of technical success and target vessel preservation were seen throughout, with 11·1 per cent of patients requiring late reintervention after FEVAR. In the majority of cases, reintervention was required due to loss of target vessel patency, graft migration and endoleak. In contrast, only 2·0 per cent of patients required reintervention more than 30 days after OSR. There are, however, a number of factors to consider when interpreting this difference. Follow‐up of patients undergoing FEVAR is rigorous, resulting in comprehensive follow‐up data, yet those undergoing OSR rarely undergo long‐term surveillance. Long‐term complications following OSR are also poorly defined, resulting in under‐reporting of interventions such as incisional hernia repair and adhesiolysis for small bowel obstruction. Thus, these confounding factors should temper the conclusion that OSR has greater 'reintervention free' durability than FEVAR.

Long‐term survival was similar for OSR and FEVAR in this meta‐analysis. Comparison of long‐term outcomes between FEVAR and OSR is limited by selection bias, which renders the two cohorts mismatched in terms of co‐morbidities and surgical fitness. The difference in surgical suitability produces measurable differences in survival. The EVAR‐1 trial[9](#bjs550178-bib-0009){ref-type="ref"} found estimated 4‐year survival to be 74 per cent, yet EVAR‐2[40](#bjs550178-bib-0040){ref-type="ref"} (those unfit for open repair) found the estimated 4‐year survival rate to be significantly lower at 44 per cent. The true long‐term effects of each intervention may reflect a similar pattern seen when comparing standard EVAR and open repair: that the initial survival benefit of EVAR is eroded over time[41](#bjs550178-bib-0041){ref-type="ref"}. To compare long‐term survival between FEVAR and OSR an RCT would be required, in order to remove selection bias and allow comparison between two equally co‐morbid groups. Given the incidence of complex AAA and the different expertise of different centres, this will be challenging to instigate.

Despite increasing technical difficulty with complex FEVAR, no difference was noted in either technical success or mortality and morbidity.

Published registry data for FEVAR are available in the Global Collaborators on Advanced Stent‐Graft Techniques for Aneurysm Repair (GLOBALSTAR) database, the French registries WINDOWS (branched and fenestrated) and ANACONDA™ (Vascutek, Inchinnan, UK) Fenestrated Endografts in the Treatment of Complex Aortic Pathologies (EFEFA), and the American College of Surgeons\' National Surgical Quality Improvement Program database. These provide data pertaining to the real‐world outcomes of complex EVAR[42](#bjs550178-bib-0042){ref-type="ref"}, [43](#bjs550178-bib-0043){ref-type="ref"}, [44](#bjs550178-bib-0044){ref-type="ref"}. Deery and colleagues[4](#bjs550178-bib-0004){ref-type="ref"} published data from the Vascular Study Group of New England, comparing the outcomes of 1875 patients who had elective open repair of AAA between 2003 and 2011. Of these, 443 patients underwent repair of complex AAA, as defined by the requirement of a suprarenal or more proximal cross‐clamp of the aorta. The 30‐day mortality rate was 3·6 per cent. Although low, this was three times higher than the 1·2 per cent rate following repair of infrarenal AAA. Rates of postoperative morbidity reflected that found in the present review; renal impairment was 20 per cent, haemodialysis was required in 1·1 per cent and myocardial infarction occurred in 7 per cent of patients. In 2017, Ultee *et al.* ^45^ compared FEVAR with OSR for complex AAA within the National Surgical Quality Improvement Program (a database consisting of results from 200 hospitals across the USA). The 30‐day mortality rate was significantly higher after OSR: 6·6 per cent *versus* 3·4 per cent after FEVAR (*P* = 0·038). Although the incidence of AKI was lower in both groups compared with findings in the present review, the odds ratio for AKI following OSR was 4·8 (95 per cent c.i. 2·2 to 10·5; *P* \< 0·001) compared with FEVAR[45](#bjs550178-bib-0045){ref-type="ref"}. In the UK, an analysis of Hospital Episode Statistics data gave a 30‐day mortality rate of 14·0 per cent after open suprarenal AAA repair[46](#bjs550178-bib-0046){ref-type="ref"}. The rate of freedom from all‐cause mortality was 78, 73, 67, 63 and 58 per cent in years 1, 2, 3, 4 and 5 after surgery respectively[46](#bjs550178-bib-0046){ref-type="ref"}. Inclusion was defined by procedural code 'Replacement of aneurysmal segment of suprarenal abdominal aorta by anastomosis of aorta to aorta'; it therefore excluded juxtarenal AAA repair and may have included type IV TAAA, which may account for the significantly higher mortality described. Analysis of the GLOBALSTAR database was used to present the UK results of FEVAR between 2007 and 2010[42](#bjs550178-bib-0042){ref-type="ref"}. The perioperative mortality rate was 4·1 per cent, the early reintervention rate (within 30 days) 7 per cent, and the rate of intraoperative target vessel loss 0·6 per cent. The survival rate was 94, 91 and 89 per cent at 1, 2 and 3 years respectively[42](#bjs550178-bib-0042){ref-type="ref"}.

The difference in baseline characteristics due to the selection bias prevalent in clinical practice highlights the inherent problem with retrospective comparison of the results of FEVAR and OSR. The reporting of long‐term results, particularly with open series, is inconsistent as these patients are not placed under routine surveillance and do not routinely undergo postprocedural imaging; follow‐up imaging was performed in only one series[26](#bjs550178-bib-0026){ref-type="ref"}, rendering commentary on graft durability after open repair difficult. Given the low prevalence of late complications after OSR, this study does not support formal surveillance for this patient group, with intervention offered if and when symptoms develop. Inclusion and exclusion criteria with respect to aneurysm morphology, which varies between FEVAR studies, are an additional confounding factor, with some including only short‐necked infrarenal aneurysms and others including those that extend proximal to the coeliac trunk. The open series define the inclusion criteria differently according to the position of aortic cross‐clamp. Thus, the two cohorts are potentially distinct in their aneurysm characteristics.

Variability in reporting of outcomes, particularly renal outcomes, may have significantly affected the conclusions drawn. FEVAR is a complex endovascular procedure, associated with a significant learning curve. To reduce the effects of this, contemporary studies were used to remove study data obtained while the technique was being developed. It should be noted, however, that although current experience of OSR outweighs that of FEVAR, the tendency towards endovascular techniques results in a shortfall in trainee experience of OSR. Results of complex OSR have likely plateaued and may begin to see a downward trend[47](#bjs550178-bib-0047){ref-type="ref"}. In contrast, the learning curve continues with FEVAR, and with further innovation in stent design and fusion imaging, results will continue to improve. The majority of high‐volume, specialized centres are located outside the UK, raising the question of whether the results are generalizable to small centres in the UK.

Owing to the heterogeneity present, both between treatment groups as a result of sampling and selection bias and between study results within a single treatment arm (as demonstrated by χ^2^ Cochrane Q score), a pooled comparison was not performed. Ideally, a randomized trial would be conducted to determine definitively which procedure patients should be offered as a first‐line intervention. In the absence of such a study, all patients undergoing complex AAA repair should be entered into mandatory registries with an agreed set of co‐morbidity and outcome data to improve the analysis of real‐world outcomes in the future.
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**Fig. S1** Funnel plot of standard error by 30‐day mortality, FEVAR (above) and OSR (below)
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Click here for additional data file.
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